AUXERIS THERAPEUTICS
Auxeris Therapeutics is a biopharmaceutical company focused on the development and commercialization of medicines to treat a broad range of bone diseases. The company develops drugs to treat fracture repair, spinal fusion, and bone diseases, including osteoporosis. Auxeris Therapeutics was founded in 2002 and is based in St. Louis, Missouri.
AUXERIS THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Medical Pharmaceutical
Founded:
2002-01-01
Address:
St Louis, Missouri, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
1.6 M USD
Similar Organizations
ANGANY
ANGANY is a pharmaceutical company that offers treatment for allergies.
Antidote Therapeutics
It operates in the biotechnology industry.
Grace Therapeutics
Grace Therapeutics is a pharmaceutical company that focuses on drug delivery treatment for rare and orphan diseases.
Merck
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Peroxitech Therapeutics
Peroxitech Therapeutics operates as a biopharmaceutical company.
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2004-01-16 | Ceros Pharmaceuticals | Ceros Pharmaceuticals acquired by Auxeris Therapeutics | N/A |
Investors List
Domain Associates
Domain Associates investment in Series A - Auxeris Therapeutics
RiverVest
RiverVest investment in Series A - Auxeris Therapeutics
More informations about "Auxeris Therapeutics"
Auxeris Therapeutics - Funding, Financials, Valuation & Investors
Auxeris Therapeutics is a biopharmaceutical company focused on the treatment of bone diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. ...See details»
Auxeris Therapeutics Company Profile | Management and
Auxeris Therapeutics, Inc. - is a biopharmaceutical company developing novel approaches to spinal and bone fusion and the treatment of bone-related diseases. Popular Searches. Auxeris …See details»
Auxeris Therapeutics - Products, Competitors, Financials, …
Headquarters Location. 4041 Forest Park Avenue . St. Louis, Missouri, 63108, United States. 314-633-1880See details»
Auxeris Therapeutics - Crunchbase
Auxeris Therapeutics is a biopharmaceutical company focused on the treatment of bone diseases. New. Resources. Advanced Search. Start Free Trial . Talk With Sales ... Experience the new …See details»
Auxeris Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Auxeris Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, , Drug:AUX-201, AUX-101 (Auxeris Therapeutics, Inc.), AUX-102.See details»
AUXERIS THERAPEUTICS - Auxeris Therapeutics, Inc. Trademark …
AUXERIS THERAPEUTICS: Mark Drawing Type: 3 - AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/ LETTER(S)/NUMBER(S) Mark Type: TRADEMARK: Standard …See details»
Auxeris Therapeutics Company Profile - Powrbot list of companies
Auxeris Therapeutics, Inc. is a privately held biopharmaceutical company focused on the development and commercialization of proprietary breakthrough medicines to treat a broad …See details»
Auxeris Therapeutics Inc. - BioCentury Company Profiles - BCIQ
Jun 28, 2004 Auxeris Therapeutics Inc. - BioCentury Company Profiles for the biopharma industrySee details»
Auxeris Therapeutics, Inc. - VentureRadar
Auxeris Therapeutics, Inc. Follow Following Show more Show less. n/a Funding Signals. VENTURE FUNDED. Domain Associates. Export Similar Companies Similar Companies. …See details»
Auxeris Therapeutics, Inc.:Company Profile & Technical Research ...
Auxeris Therapeutics is headquartered in United States Missouri. Auxeris Therapeutics was founded in 2002. Auxeris Therapeutics has a total of 1 patents . Related Topics. Health care …See details»
6 Top BioPharma Startups & Companies (St Louis)
Confluence is a contract research organization providing mechanistic enzymology, target validation, characterization, and more. ... Learn more about their finances on Crunchbase. …See details»
Auxeris Therapeutics - Overview, News & Similar companies
Auxeris Therapeutics's headquarters are located at 4041 Forest Park Ave, St. Louis, Missouri, 63108, United States What is Auxeris Therapeutics's official website?See details»
Auxeris Therapeutics CEO, Founder, Key Executive Team, Board of ...
Auxeris Therapeutics has 2 board of directors, including Brian Halak. Name. Firm. Work History. Other Seats. Brian Halak. As part of Domain Associates since 2001, and a Partner since 2006, …See details»
Auxeris Therapeutics - Tech Stack, Apps, Patents & Trademarks
Auxeris Therapeutics is a biopharmaceutical company focused on the treatment of bone diseases. New. Resources. Advanced Search. Start Free Trial . Talk With Sales ... Experience the new …See details»
AUXERIS - Auxeris Therapeutics, Inc. Trademark Registration
Mark For: AUXERIS™ trademark registration is intended to cover the categories of printed matter, namely, printed guides, press releases, product guides, and reports in the fields of medicine, …See details»
AUX-101 (Auxeris Therapeutics, Inc.) - Drug Targets, Indications ...
AUX-101 (Auxeris Therapeutics, Inc.): a Osteogenesis stimulants Drug, Initially developed by Auxeris Therapeutics, Inc., Now, its global highest R&D status is Discontinued, Mechanism: …See details»
Auxeris Focusing Products On Bone Loss Prevention, Disease
Apr 12, 2004 Auxeris is developing therapeutics for bone diseases, such as osteoporosis and bone metastasis. The company wants to prevent or reverse bone loss, as opposed to just …See details»
Auxeris Therapeutics - Updates, News, Events, Signals & Triggers
Jan 16, 2004 Auxeris Therapeutics raised $1,600,000 / Series A from Domain Associates and RiverVest Discover more funding rounds Browse By: Organizations, People, EventsSee details»
New study results reinforce Tagrisso as the backbone therapy for …
1 day ago New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy …See details»
Ceros Pharmaceuticals acquired by Auxeris Therapeutics
Jan 16, 2004 Auxeris Therapeutics acquires Ceros Pharmaceuticals on 2004-01-16 for an undisclosed amount. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. …See details»